Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BMS-986263 in Adults With Compensated Cirrhosis Due to NASH
jRCT2011200024Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of ND-L02-s0201 in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Improvement in liver fibrosis as determined by liver biopsy. Started Mar 2021; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on jRCT2011200024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200024.